Smith & Nephew (LON:SN) Earns Neutral Rating from UBS Group
UBS Group reaffirmed their neutral rating on shares of Smith & Nephew (LON:SN) in a research note released on Monday morning, Stock Target Advisor reports.
A number of other brokerages have also issued reports on SN. Jefferies Financial Group cut their price target on shares of Smith & Nephew from GBX 2,200 ($28.94) to GBX 2,160 ($28.41) and set a buy rating on the stock in a research note on Tuesday, January 21st. JPMorgan Chase & Co. reiterated a neutral rating on shares of Smith & Nephew in a research note on Wednesday, February 5th. Shore Capital reiterated a sell rating on shares of Smith & Nephew in a research note on Friday, January 24th. Citigroup started coverage on shares of Smith & Nephew in a research note on Thursday, November 21st. They set a buy rating on the stock. Finally, Credit Suisse Group cut their price target on shares of Smith & Nephew from GBX 1,770 ($23.28) to GBX 1,725 ($22.69) and set a neutral rating on the stock in a research note on Monday, November 4th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have issued a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of GBX 1,898.50 ($24.97).
Shares of LON:SN opened at GBX 1,845 ($24.27) on Monday. The company has a debt-to-equity ratio of 44.00, a current ratio of 2.00 and a quick ratio of 0.96. The firm has a market capitalization of $16.15 billion and a PE ratio of 23.15. The firm’s 50-day moving average is GBX 1,862.40 and its two-hundred day moving average is GBX 1,829.66. Smith & Nephew has a 1 year low of GBX 1,417 ($18.64) and a 1 year high of GBX 1,998.40 ($26.29).
Smith & Nephew plc develops, manufactures, and sells medical devices worldwide. The company offers sports medicine joint repair products for surgeons, including an array of instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder.
Featured Article: Analyst Ratings Trading
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.